Multi-biomaker NGS assay for solid tumors that evaluates >500 genes for SNVs, Indels, CNVs, LOH, Gene Fusions and also includes TMB and MSI. (FFPE samples)
Multi-biomaker NGS assay that covers 161 of the most clinically relevant cancer genes in solid tumors (FFPE samples)
We evaluate 5 markers in samples containing mismatch repair defects in solid tumors (FFPE affected + non-affected tissue samples)
Includes 19 relevant genes for colorectal cancer assessment including MMR (mismatch repair pathway) genes: MLH1, MSH2, MSH6 and PMS2
Somatic and germline patogenic variants for BRCA1 and BRCA2 genes (FFPE + blood)
Analysis of 21 cancer genes including homologus repair pathway and MMR in FFPE biopsies
(Germline testing also available)
Analysis of 39 genes relevant in Hereditary Cancer Syndromes (germline mutations)
Using 1 single blood sample we evaluate 52 clinically relevant genes from cell-free DNA (cfDNA) and cell-free RNA (cfRNA) found in the plasma fraction of whole blood.
Using 1 single blood sample we assay 14 clinically relevant genes in colorectal cancer from cell-free DNA (cfDNA) found in the plasma fraction of whole blood.
Using 1 single blood sample we test 12 clinically relevant genes in breast cancer from cell-free DNA (cfDNA) found in the plasma fraction of whole blood.
Using 1 single blood sample this test evaluates 12 clinically relevant genes in lung cancer from cell-free DNA (cfDNA) and cell-free RNA (cfRNA) found in the plasma fraction of whole blood.